On August 18, 2026, UroGen Pharma Ltd. entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd., securing an exclusive worldwide option to license the TumoCure product and SRGel platform for advanced head and neck cancer treatment. The company also signed a Securities Purchase Agreement to invest up to $7,000,000 in IntraGel's equity securities. UroGen Pharma Ltd. operates in the biopharmaceutical industry, focusing on the development of therapies for urological diseases.

UroGen Pharma Ltd. reported second quarter 2026 financial results, announcing total revenue of $72.5 million compared to $24.2 million in the prior year period. ZUSDURI generated $50.4 million in net product revenue, reflecting 73% quarter-over-quarter growth, while JELMYTO contributed $22.0 million. The company reported a net loss of $14.4 million, or $0.28 per share, narrowing from the $49.9 million loss recorded in Q2 2025. UroGen increased its full-year 2026 operating expense guidance to a range of $260 million to $270 million and maintained JELMYTO revenue expectations between $97 million and $101 million. The firm remains on track for a third quarter NDA submission for UGN-103 and expects to initiate a Phase 1 trial for UGN-501 in the fourth quarter of 2026.

At its 2026 Annual Meeting of Shareholders held on June 22, 2026, UroGen Pharma Ltd. shareholders approved several key proposals. These included the amendment and restatement of the company's Articles of Association to align shareholder proposal eligibility with Israeli Companies Law, an amendment to the Non-Employee Director and Officer Compensation Policy regarding insurance, and an amendment to the 2017 Equity Incentive Plan to increase authorized ordinary shares by 1,000,000. Additionally, shareholders elected seven directors, approved advisory say-on-pay, and ratified PricewaterhouseCoopers LLP as the independent auditor. UroGen Pharma Ltd. is a biopharmaceutical company focused on developing therapies for urological diseases.